Gland Pharma Share Price Target 2025, 2026, 2027, 2028, 2030:- The company was incorporated in 1956 in Hyderabad as a limited company, Gland Pharma, and received a certificate of incorporation from the Registrar of Companies in Hyderabad, Andhra Pradesh.
Therefore, in this article, we attempt to provide a fresh perspective on Gland Pharma shares through technical and fundamental analysis.
Gland Pharma Share Price Target 2025
In 1994, the company’s name was changed to Gland Pharma through a special resolution passed by the company’s shareholders, and as a result of this change, a new Memorandum of Association was issued by the Registrar of Companies in Hyderabad, Andhra Pradesh in 1995. It transitioned into a limited company in 1956. From 2014 to 2019, it was one of the fastest-growing generic injectables companies in the United States in terms of revenue. The company primarily sells its products under a brand name in various countries, including the United States, Europe, Canada, Australia, India, and the rest of the world.
The initial price target for Gland Pharma shares in 2025 is expected to be around ₹1800, and the second target price for Gland Pharma will be ₹2150.
| Months | Gland Pharma Share Price Target 2025 |
|---|---|
| January 2025 | Rs 1800 |
| February 2025 | Rs 1810 |
| March 2025 | Rs 1830 |
| April 2025 | Rs 1850 |
| May 2025 | Rs 1870 |
| June 2025 | Rs 1900 |
| July 2025 | Rs 1930 |
| August 2025 | Rs 1970 |
| September 2025 | Rs 2000 |
| October 2025 | Rs 2040 |
| November 2025 | Rs 2100 |
| December 2025 | Rs 2150 |
Gland Pharma Share Price Target 2026
Gland Pharma has a consistent track record of complying with various regulatory frameworks in these markets. They possess extensive experience in the development, manufacturing, and marketing of complex injectable products, and have a strong understanding of the sophisticated scientific, technical, and regulatory processes involved. Established in 1978 in Hyderabad, India, the company has expanded from liquid parenterals to other elements of the injectable value chain, including contract development, in-house development, documentation preparation and filing, technology transfer, and manufacturing across a range of application systems.
The first share price target for Gland Pharma in 2026 is estimated to be ₹2200, while the second target could be approximately ₹2650.
| Months | Gland Pharma Share Price Target 2026 |
|---|---|
| January 2026 | Rs 2200 |
| February 2026 | Rs 2230 |
| March 2026 | Rs 2250 |
| April 2026 | Rs 2270 |
| May 2026 | Rs 2290 |
| June 2026 | Rs 2340 |
| July 2026 | Rs 2380 |
| August 2026 | Rs 2450 |
| September 2026 | Rs 2480 |
| October 2026 | Rs 2540 |
| November 2026 | Rs 2600 |
| December 2026 | Rs 2650 |
Gland Pharma Share Price Target 2027
Gland Pharma has a professional management team, and one of its promoters, Shanghai Fosun Pharma, is a global pharmaceutical company. The company focuses on meeting diverse needs in the injectable sector with a steady supply of affordable and high-quality products. It has established a portfolio of injectable products across various therapeutic areas and application systems. Gland Pharma is present in sterile injectables, oncology, and ophthalmology, with a focus on complex injectable applications. Its delivery systems include liquid vials, lyophilized vials, prefilled syringes, ampoules, pouches, and drops.
The first share price target for Gland Pharma in 2027 is ₹2700, and the second target could exceed ₹3140.
| Months | Gland Pharma Share Price Target 2027 |
|---|---|
| January 2027 | Rs 2700 |
| February 2027 | Rs 2750 |
| March 2027 | Rs 2800 |
| April 2027 | Rs 2840 |
| May 2027 | Rs 2870 |
| June 2027 | Rs 2920 |
| July 2027 | Rs 2950 |
| August 2027 | Rs 3000 |
| September 2027 | Rs 3040 |
| October 2027 | Rs 3070 |
| November 2027 | Rs 3100 |
| December 2027 | Rs 3140 |
Gland Pharma Share Price Target 2028
Gland Pharma has expanded its development and manufacturing capabilities to include complex injectables such as peptides, long-acting injectables, suspensions, and hormonal products, as well as new delivery systems like pens and cartridges. Gland Pharma, through its partner, has launched Bortezomib for Injection, 3.5 mg/vial, a single-dose vial, in the U.S. This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial, from Takeda Pharmaceuticals U.S.A., Inc. Bortezomib for Injection is used to treat certain types of cancer, such as multiple myeloma and mantle cell lymphoma.
The first share price target for Gland Pharma in 2028 is ₹3200, and the second target for FY 2028 is expected to be around ₹3700.
| Months | Gland Pharma Share Price Target 2028 |
|---|---|
| January 2028 | Rs 3200 |
| February 2028 | Rs 3240 |
| March 2028 | Rs 3280 |
| April 2028 | Rs 3320 |
| May 2028 | Rs 3350 |
| June 2028 | Rs 3400 |
| July 2028 | Rs 3450 |
| August 2028 | Rs 3480 |
| September 2028 | Rs 3530 |
| October 2028 | Rs 3580 |
| November 2028 | Rs 3640 |
| December 2028 | Rs 3700 |
Gland Pharma Share Price Target 2030
Gland Pharma is engaged in complex injectables, contract development, and biosimilar manufacturing to accelerate short-term growth. The company has made significant progress in research and development regarding the planned launch of complex injectable doses scheduled for the current fiscal year. Gland Pharma is on track to complete four complex injectables this fiscal year. In the near future, the company is focusing on building a strong portfolio of complex injectable formulations. It is also looking at acquisition opportunities that will help accelerate its growth process. The setup for new lines for the administration of suspensions and hormonal preparations has been completed.
The first share price target for Gland Pharma in 2030 is expected to be ₹5200, and the second price target for Gland Pharma stock could reach ₹6000 by the end of FY 2030.
| Months | Gland Pharma Share Price Target 2030 |
|---|---|
| January 2030 | Rs 5200 |
| February 2030 | Rs 5250 |
| March 2030 | Rs 5300 |
| April 2030 | Rs 5400 |
| May 2030 | Rs 5450 |
| June 2030 | Rs 5550 |
| July 2030 | Rs 5600 |
| August 2030 | Rs 5650 |
| September 2030 | Rs 5700 |
| October 2030 | Rs 5800 |
| November 2030 | Rs 5900 |
| December 2030 | Rs 6000 |
Future Prospectus of Gland Pharma Share
Gland Pharma is actively involved in complex injectables, contract development, and biosimilar manufacturing to accelerate short-term growth.
The company has expanded its development and manufacturing capabilities to include complex injectables such as peptides, long-acting injectables, suspensions, and hormonal products, as well as new delivery systems like pens and cartridges.
Gland Pharma Share F.A.Q.
– Where is Gland Pharma’s headquarters located?
Gland Pharma’s headquarters is in Hyderabad.
– Who is the current MD of Gland Pharma?
The current MD of Gland Pharma is from Shanghai Fosun.
– What business does Gland Pharma engage in?
Gland Pharma is involved in the development, manufacturing, and sale of complex injectable formulations. The company primarily sells its products in various countries under a business-to-business model.
I hope that after reading the article on Gland Pharma Share Price Targets for 2025, 2026, 2027, 2028, and 2030, you now have a good idea of the potential performance of the company’s growth. If you still have any questions related to this article, don’t forget to mention them in the comments. For important information about stocks like this in the stock market, stay connected with Market in India.
Also read:-